AAP Updates Influenza Vaccination Guidance for Children
Routine annual influenza vaccination is recommended for all patients 6 months of age and older who have no medical contraindications.
Influenza
ACIP: Updated Vaccine Guidance for the 2021-2022 Influenza Season
Routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications.
Influenza Antiviral Treatments
FDA-approved antiviral therapies for the treatment and prophylaxis of influenza.
Antiviral Drugs for Influenza: Safety and Efficacy Outcomes Compared
The study authors obtained randomized clinical trials comparing oseltamivir, peramivir, zanamivir, and baloxavir with other active agents or placebo.
Flucelvax Quadrivalent Approval Expanded to Include Younger Patients
Flucelvax Quadrivalent is a subunit influenza vaccine manufactured using cell derived candidate vaccine viruses; it does not contain egg proteins or antibiotics.
Children Given Flu Shot Less Likely to Have Symptomatic COVID-19
Odds also lower for having severe disease for patients vaccinated for influenza, pneumococcal disease
Updates to the 2021 Adult Immunization Schedule
The ACIP emphasizes the importance of routine vaccinations during the pandemic to prevent diseases.
Rapivab Approval Expanded to Include Younger Patients With Influenza
In the peramivir arm, the median time to alleviation of combined influenza symptoms was 79 hours compared with 100 hours in the oseltamivir arm.
Risk for Death, Complications Higher With COVID-19 Versus Flu
Risk for mechanical ventilation use, admission to intensive care, longer length of stay increased for COVID-19 versus flu
Xofluza Approved for Postexposure Prevention of Influenza
The approval was supported by data from the randomized, double-blind, placebo-controlled phase 3 Blockstone trial.
